Study sheds light on benefits of exercise for people with peripheral artery disease edexlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from edexlive.com Daily Mail and Mail on Sunday newspapers.
High-intensity walking exercise benefits people with peripheral artery disease
No pain means no gain when it comes to reaping exercise benefits for people with peripheral artery disease (PAD), reports a new Northwestern Medicine study.
In people with peripheral artery disease, walking for exercise at an intensity that induces ischemic leg pain (caused by restricted blood flow) improves walking performance distance and length of time walking the study found. Walking at a slow pace that does not induce ischemic leg symptoms is no more effective than no exercise at all, the study showed.
This randomized trial is the first to show that a home-based walking exercise program improved walking ability in people with peripheral artery disease when exercise was conducted at a high intensity that induced ischemic leg symptoms but not when the exercise was conducted at a low intensity without ischemic leg symptoms.
email article
Peripheral artery disease (PAD) patients with intermittent claudication could walk better after a year of regular home-based exercise at high intensity, whereas a low-intensity program was not effective at all, researchers reported.
Only one arm of the 305-person LITE trial showed improvements on the 6-minute walk test:
High-intensity exercise group: average 338.1 m at baseline to 371.2 m at 12 months (
P
Share this article
SEATTLE, April 6, 2021 /PRNewswire/ Umoja Biopharma, a biotechnology company pioneering an integrated,
in vivo immunotherapy platform, today announced the appointment of Nushmia Khokhar, M.D., as Chief Medical Officer.
Nushmia Khokhar, MD, Chief Medical Officer We are excited to welcome Dr. Khokhar to the Umoja team. Nushmia is an accomplished oncologist who has spent a significant portion of her career overseeing the transition of novel cancer therapeutics from discovery to clinical development, said Andy Scharenberg, M.D., co-founder and CEO of Umoja. Her expertise across early and late-stage clinical development will be invaluable to the company during a milestone year.
Maria Fabrizio for STAT
Weeks after it was scrubbed from the Journal of the American Medical Association’s website, a disastrous podcast whose host, a white editor and physician, questioned whether racism even exists in medicine is surfacing complaints that JAMA and other elite medical journals have routinely excluded, minimized, and mishandled issues of race.
Recent examples include research blaming higher death rates from Covid-19 in African Americans on a single gene in their nasal passages; a letter claiming structural racism doesn’t play a role in pulse oximeters working less well on patients with dark skin because machines can’t exhibit bias; and an article claiming that students of programs designed to increase diversity in medicine won’t make good doctors.